VEGFR3: a new target for antiangiogenesis therapy? (Q38973271)

8 September 2017

VEGFR3: a new target for antiangiogenesis therapy? (English)

1 reference

8 September 2017

1

1 reference

8 September 2017

2

Rakesh K Jain

1 reference

PMCID

4790102

8 September 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

8 September 2017

2

1 reference

based on heuristic

inferred from page(s)

published in

Developmental Cell

1 reference

8 September 2017

15

1 reference

8 September 2017

2

1 reference

8 September 2017

178-179

1 reference

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

8 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4790102

Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4790102

Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4790102

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4790102

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4790102

Cardiovascular failure in mouse embryos deficient in VEGF receptor-3

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4790102

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4790102

Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4790102

Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4790102

10.1016/J.DEVCEL.2008.07.014

2 December 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference

8 September 2017

1 reference

PMCID

4790102